DUAL-REGISTERED PROTOCOL // OSF PRE-REGISTERED (DOI: 10.17605/OSF.IO/VPS9D) · CLINICALTRIALS.GOV PRS IN PROGRESS · PROTOCOL ID: DS-CLIN-2026-EPI-RESOLVE · PLANNED N = 10,000
EPI-RESOLVE™ Registry.
Root-cause discovery in drug-resistant epilepsy.
Over 30% of epilepsy patients are labeled medically intractable, cycled through combinations of anti-seizure medications while root-cause gut-brain, metabolic, and marrow disruptions remain uninvestigated. EPI-RESOLVE™ is a global, prospective decentralized clinical registry ($N=10,000$) investigating multi-system biomarker tensors under the DeepSensi Cognitive Engine. Participation in the clinical registry is 100% Free.
RESOLVE in the United States: in preparation (IRB submission in preparation, the first country to open).
Registry Strata
Three Core Epilepsy Pathology Cohorts
Pediatric Drug-Resistant Epilepsy & DEE
Children failure on ≥ 2 anti-seizure medications, Lennox-Gastaut Syndrome, West Syndrome, and unclassified developmental and epileptic encephalopathies.
Monogenic Channelopathies & SCN1A
Confirmed or suspected monogenic epilepsy variants (SCN1A/Dravet, SCN2A, KCNQ2, PCDH19, STXBP1, CDKL5) exploring ion-channel pharmacogenomic interactions.
Adult Intractable & Structural Epilepsy
Adults with persistent focal or generalized seizures despite polypharmacy, post-traumatic epilepsy, or metabolic neurodegeneration.
From routine care, ordered by each participant's own physicians, the registry also records urine organic acids and a metagenomic stool profile, through which it observes the gut-brain axis, and antiseizure medication levels.
DeepSensi DCT
